122350-52-1

Basic information

• Product Name: FMOC-GLU-OBZL
• Synonyms: N-ALPHA-FMOC-L-GLUTAMIC ACID ALPHA-BENZYL ESTER;N-ALPHA-(9-FLUORENYLMETHOXYCARBONYL)-L-GLUTAMIC ACID-ALPHA-BENZYL ESTER;FMOC-GLU-OBZL;(S)-4-(((9H-fluoren-9-yl)methyl9H-fluoren-9-yl)methoxy)carbonylamino)-5-(benzyloxy)-5-oxopentanoic acid;Fmoc-L-glutamic acid alpha-benzyl ester;(4S)-5-(Benzyloxy)-4-{[(9H-fluoren-9-ylMethoxy)carbonyl]aMino}-5-oxopentanoic acid (non-preferred naMe);(S)-4-((((9H-Fluoren-9-yl)Methoxy)carbonyl)aMino)-5-(benzyloxy)-5-oxopentanoic acid;N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-glutamic acid 1-(phenylmethyl) ester
• CAS NO: 122350-52-1
• Molecular Formula: C₂₇H₂₅NO₆
• Molecular Weight: 459.49
• Mol File: 122350-52-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 702.9±60.0 °C(Predicted)
• Appearance: White/Powder
• Density: 1.289±0.06 g/cm3(Predicted)
• Storage Temp.: Store at RT.
• PKA: 4.46±0.10(Predicted)
• CAS DataBase Reference: FMOC-GLU-OBZL(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-GLU-OBZL(122350-52-1)
• EPA Substance Registry System: FMOC-GLU-OBZL(122350-52-1)

Safety Data

• Hazardous Substances Data: 122350-52-1(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white powder

Upstream product

• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 56-86-0 L-glutamic acid 
• 104091-09-0 (S)-2-[{({9H-fluoren-9-yl}methoxy)carbonyl}amino]pentanedioic acid 
• 100-39-0 benzyl bromide 
• 100-51-6 benzyl alcohol 
• 100-44-7 benzyl chloride 
• 84418-43-9 9-fluorenylmethyl carbamate 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 13030-09-6 1-benzyl L-glutamate 
• 71989-18-9 Fmoc-Glu(OtBu)-OH 
• 154672-63-6 Benzyl ester of α-N-(9-fluorenylmethoxycarbonyl)-γ-tert-butyl ester of L-glutamic acid 

Downstream Products

• 178181-74-3 benzyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-hydroxypentanoate 
• 178181-75-4 (S)-5-[(3aS,4R,6R,7R,7aR)-4-(tert-Butyl-diphenyl-silanyloxymethyl)-7-hydroxy-2,2-dimethyl-tetrahydro-[1,3]dioxolo[4,5-c]pyran-6-yloxy]-2-(9H-fluoren-9-ylmethoxycarbonylamino)-pentanoic acid benzyl ester 
• 1255956-21-8 Fmoc-L-Glu(NHCH₂(CH₂CH₂O)3(CH₂)3NHBoc)-OBn 
• 1415221-96-3 benzyl N--Fmoc--(2S)--2--amino--5--oxo--5--((7--phenylheptyl)amino)pentanoate 
• 1415221-86-1 N--Fmoc--(2S)--2--amino--5--oxo--5--((7--phenylheptyl)amino)pentanoic acid 

Relevant articles and documents

Preparation method of N-fluorenylmethoxycarbonyl-gamma-(S-triphenylmethyl-cysteamine)-L-glutamic acid

The invention provides a preparation method of N-fluorenylmethoxycarbonyl-gamma-(S-triphenylmethyl-cysteamine)-L-glutamic acid. The preparation method mainly solves the technical problems of complexity, long period, high cost, and low yield of an original process, and comprises the following steps: (1) preparing N-fluorenylmethoxycarbonyl-L-glutamic acid; (2) preparing N-fluorenylmethoxycarbonyl-L-glutamic acid-1-benzyl ester; (3) preparing S-triphenylmethyl cysteamine; (4) preparing N-fluorenylmethoxycarbonyl-gamma-(S-triphenylmethyl-cysteamine)-L-glutamic acid-alpha-benzyl ester; and (5) preparing N-fluorenylmethoxycarbonyl-gamma-(S-triphenylmethyl-cysteamine)-L-glutamic acid. The method is rapid, high in yield and simple in separation and purification, and the used solvent is environment-friendly and is suitable for mass production.

Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1)

We report herein that incorporating long-chain alkylphenyl-containing non-proteinogenic amino acids in place of His at the pT-2 position of the parent polo-like kinase 1 (Plk1) polo box domain (PBD)-binding pentapeptide, PLHSpT (1a) increases affinity. Fo

Novel synthesis of cyclic amide-linked analogues of angiotensins II and III

Cyclic amide-linked angiotensin II (ANGII) analogues have been synthesized by novel strategies, in an attempt to test the ring clustering and the charge relay bioactive conformation recently suggested. These analogues were synthesized by connecting side chain amino and carboxyl groups at positions 1 and 8, 2 and 8, 3 and 8, and 3 and 5, N-terminal amino and C-terminal carboxyl groups at positions 1 and 8, 2 and 8, and 4 and 8, and side chain amino to C-terminal carboxyl group at positions 1 and 8. All these analogues were biologically inactive, except for cyclic [Sar1,Asp3,Lys5]ANGII (analogue 10) which had high contractile activity in the rat uterus assay (30% of ANGII) and [Lys1,Tyr(Me)4,Glu8]ANGII (analogue 7) which had weak antagonist activity (PA2 ? 6). Precyclic linear peptides synthesized using 2-chlorotrityl chloride resin and N(α)-Fmoc-amino acids with suitable side chain protection were obtained in high yield and purity and were readily cyclized with benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate as coupling reagent. Molecular modeling suggests that the ring structure of the potent analogue can be accommodated in the charge relay conformation proposed for ANGII.